OcuLief™

The Challenge
  • Visual impairment is a significant health and economic problem worldwide.
  • The estimated number of people visually impaired in the world is 285 million, 39 million blind and 256 million having low vision. 65% of people visually impaired and 82% of all blind are 50 years and older.
  • The global cost of vision loss is nearly £2.46 trillion for the 733 million people living with low vision and blindness worldwide in 2010.
  • Every day around 250 people in the UK start to lose their sight.
Our Solution – OcuLief™

Our aim is to overcome the current need for monthly injection of medicine to treat chronic eye diseases (e.g. AMD). OcuLief is tailored for the treatment of AMD, DR and DME by long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 4-6 months or more.

Advantages of OcuLief™
  • Drug-loaded gels can be administered using conventional hypodermic needles (e.g. 27G or smaller)
  • Materials used in implant preparation are biocompatible & biodegradable
  • Allows localised drug delivery at various sites within and around the eye
  • Sustained and tailored drug delivery for 4-6 months or more.
  • Ability to deliver wide range of molecules, including proteins and peptides
  • Simple and scalable formulation approach

Advantages of OcuLief™

  • Drug-loaded gels can be administered using conventional hypodermic needles (e.g. 27G or smaller)
  • Materials used in implant preparation are biocompatible & biodegradable
  • Allows localised drug delivery at various sites within and around the eye
  • Sustained and tailored drug delivery for 4-6 months or more
  • Ability to deliver wide range of molecules, including proteins and peptides
  • Simple and scalable formulation approach

CONTACT US

United Kingdom
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA

T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing
Re-Vana Therapeutics Ltd 
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA

OPPORTUNITIES


Check back for opportunities.

PARTNERSHIPS

Re-Vana collaborates and is open to business development partnerships to deliver both small and large molecules with our technology platforms.

To discuss please contact Michael O’Rourke CEO on (+1) 813 323 1438  (Tampa Florida) or mor.revana@gmail.com

Our Products

EyeLief™

EyeLief™ is a novel photocrosslinked sustained-release preformed biodegradable implant delivering large and small therapeutics for 4-6 months or more.

OcuLief™

OcuLief™ is a novel photocrosslinked biodegradable gel implant for the sustained release of large and small therapeutics for 4-6 months or more.

NICOX ENTERS RESEARCH COLLABORATION WITH RE-VANA THERAPEUTICS

Re-Vana's technology offers us additional opportunities, alongside our recently announced collaboration with pSivida, to explore the potential for sustained-release delivery of our novel, next generation of stand-alone NO-donors. EyeLief(TM) technology has a number of unique properties that have shown promise in the delivery of drugs for the reduction of IOP. We look forward to working with Re-Vana on this innovative research endeavor.
Michael Bergamini, Executive Vice President and Chief Scientific Officer, Nicox

RE-VANA'S DESIGN STRATEGY

The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.

CONTACT US

United Kingdom
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA

T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing

Re-Vana Therapeutics Ltd
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA